Alzheimer’s disease (AD) is a multifactorial condition in which, along with amyloid-β (Aβ) and tau-related pathology, the synergistic activity of co-morbidity factors promote the onset and progression of the disease. Epidemiological evidence indicates that glucose intolerance, deficits in insulin secretion, or type-2 diabetes mellitus (T2DM) participate in increasing cognitive impairment or dementia risk. Insulin plays a pivotal role in the process as the hormone critically regulates brain functioning. GLP-1, the glucagon-like peptide 1, facilitates insulin signaling, regulates glucose homeostasis, and modulates synaptic plasticity. Exenatide is a synthetic GLP-1 analog employed in T2DM. However, exenatide has also been shown to affect the signaling of the brain-derived neurotrophic factor (BDNF), synaptic plasticity, and cognitive performances in animal models. In this study, we tested whether exenatide exerts neuroprotection in a preclinical AD model set to mimic the clinical complexity of the human disease. We investigated the effects of exenatide treatment in 3xTg-AD mice challenged with a high-fat diet (HFD). Endpoints of the study were variations in systemic metabolism, insulin and neurotrophic signaling, neuroinflammation, Aβ and tau pathology, and cognitive performances. Results of the study indicate that exenatide reverts the adverse changes of BDNF signaling and the neuroinflammation status of 3xTg-AD mice undergoing HFD without affecting systemic metabolism or promoting changes in cognitive performances.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
2.
MorrisGP, ClarkIA, VisselB (2018) Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol136, 663–689.
3.
SensiSL (2018) Alzheimer disease, time to turn the tide. Aging (Albany NY)10, 2537–2538.
4.
de la TorreJC (2012) A turning point for Alzheimer’s diseaseBioFactors38, 78–83.
5.
NuceraA, HachinskiV (2018) Cerebrovascular and Alzheimer disease: Fellow travelers or partners in crimeJ Neurochem144, 513–516.
BoylePA, YuL, WilsonRS, LeurgansSE, SchneiderJA, BennettDA (2018) Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol83, 74–83.
8.
SensiSL, GranzottoA, SiottoM, SquittiR (2018) Copper and zinc dysregulation in Alzheimer’s disease. Trends Pharmacol Sci39, 1049–1063.
9.
FrölichL, Blum-DegenD, BernsteinH-G, EngelsbergerS, HumrichJ, LauferS, MuschnerD, ThalheimerA, TürkA, HoyerS, ZöchlingR, BoisslKW, JellingerK, RiedererP (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm105, 423.
10.
HoyerS (2004) Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: Therapeutic implications. Adv Exp Med Biol541, 135–152.
11.
CraftS (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol66, 300–305.
12.
ArnoldSE, ArvanitakisZ, Macauley-RambachSL, KoenigAM, WangH-Y, AhimaRS, CraftS, GandyS, BuettnerC, StoeckelLE, HoltzmanDM, NathanDM (2018) Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nat Rev Neurol14, 168–181.
13.
StanleyM, MacauleySL, HoltzmanDM (2016) Changes in insulin and insulin signaling in Alzheimer’s disease: Cause or consequenceJ Exp Med213, 1375–1385.
CraftS (2007) Insulin resistance and Alzheimer’s disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res4, 147–152.
16.
CraftS, Stennis WatsonG (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol3, 169–178.
17.
De FeliceFG, LourencoMV, FerreiraST (2014) How does brain insulin resistance develop in Alzheimer’s disease?Alzheimers Dement10, S26–S32.
18.
CampbellJE, DruckerDJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab17, 819–837.
19.
HolstJJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev87, 1409–1439.
20.
AbbasT, FaivreE, HölscherC (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res205, 265–271.
21.
HamiltonA, HölscherC (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport20, 1161–1166.
22.
DuringMJ, CaoL, ZuzgaDS, FrancisJS, FitzsimonsHL, JiaoX, BlandRJ, KlugmannM, BanksWA, DruckerDJ, HaileCN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med9, 1173–1179.
23.
HamiltonA, PattersonS, PorterD, GaultVA, HolscherC (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res89, 481–489.
PerryTA, GreigNH (2004) A new Alzheimer’s disease interventive strategy: GLP-1. Curr Drug Targets5, 565–571.
26.
BombaM, CiavardelliD, SilvestriE, CanzonieroLM, LattanzioR, ChiappiniP, PiantelliM, Di IlioC, ConsoliA, SensiSL (2013) Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis4, e612.
27.
BombaM, GranzottoA, CastelliV, MassettiN, SilvestriE, CanzonieroLMT, CiminiA, SensiSL (2018) Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging64, 33–43.
28.
HölscherC (2014) New drug treatments show neuroprotective effects in Alzheimer’s and Parkinson’s diseases. Neural Regen Res9, 1870–1873.
29.
AthaudaD, FoltynieT (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: Mechanisms of action. Drug Discov Today21, 802–818.
30.
AthaudaD, FoltynieT (2018) Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease. Neuropharmacology136, 260–270.
31.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles. Neuron39, 409–421.
32.
AyalaJE, SamuelVT, MortonGJ, ObiciS, CronigerCM, ShulmanGI, WassermanDH, McGuinnessOP, NIH Mouse Metabolic Phenotyping Center Consortium (2010) Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech3, 525–534.
33.
IsopiE, GranzottoA, CoronaC, BombaM, CiavardelliD, CurcioM, CanzonieroLMT, NavarraR, LattanzioR, PiantelliM, SensiSL (2015) Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer’s disease without reducing amyloid and tau pathology. Neurobiol Dis81, 214–224.
34.
FrazziniV, GranzottoA, BombaM, MassettiN, CastelliV, d’AuroraM, PunziM, IorioM, MoscaA, Delli PizziS, GattaV, CiminiA, SensiSL (2018) The pharmacological perturbation of brain zinc impairs BDNF-related signaling and the cognitive performances of young mice. Sci Rep8, 9768.
35.
WeitznerDS, Engler-ChiurazziEB, KotilinekLA, AsheKH, ReedMN (2015) Morris water maze test: Optimization for mouse strain and testing environment. J Vis Exp, e52706.
36.
MasciopintoF, Di PietroN, CoronaC, BombaM, PipinoC, CurcioM, Di CastelnuovoA, CiavardelliD, SilvestriE, CanzonieroLM, SeklerI, PandolfiA, SensiSL (2012) Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis3, e448.
KothariV, LuoY, TornabeneT, O’NeillAM, GreeneMW, GeethaT, BabuJR (2017) High fat diet induces brain insulin resistance and cognitive impairment in mice. Biochim Biophys Acta1863, 499–508.
39.
JulienC, TremblayC, PhivilayA, BerthiaumeL, EmondV, JulienP, CalonF (2010) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging31, 1516–1531.
40.
VandalM, WhitePJ, TremblayC, St-AmourI, ChevrierG, EmondV, LefrancoisD, VirgiliJ, PlanelE, GiguereY, MaretteA, CalonF (2014) Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes63, 4291–4301.
Abdel-MaksoudSM, HassaneinSI, GoharNA, AttiaSMM, GadMZ (2017) Investigation of brain-derived neurotrophic factor (BDNF) gene expression in hypothalamus of obese rats: Modulation by omega-3 fatty acids. Nutr Neurosci20, 443–448.
43.
YoshiiA, Constantine-PatonM (2007) BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat Neurosci10, 702–711.
44.
GreengardP, ValtortaF, CzernikAJ, BenfenatiF (1993) Synaptic vesicle phosphoproteins and regulation of synaptic function. Science259, 780–785.
45.
BomfimTR, Forny-GermanoL, SathlerLB, Brito-MoreiraJ, HouzelJ-C, DeckerH, SilvermanMA, KaziH, MeloHM, McCleanPL, HolscherC, ArnoldSE, TalbotK, KleinWL, MunozDP, FerreiraST, De FeliceFG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Aβ oligomers. J Clin Invest122, 1339–1353.
46.
WooNH, TengHK, SiaoC-J, ChiaruttiniC, PangPT, MilnerTA, HempsteadBL, LuB (2005) Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci8, 1069–1077.
MorrisRGM, GarrudP, RawlinsJNP, O’KeefeJ (1982) Place navigation impaired in rats with hippocampal lesions. Nature297, 681–683.
53.
SalcedoI, TweedieD, LiY, GreigNH (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol166, 1586–1599.
54.
HeydemannA (2016) An overview of murine high fat diet as a model for type 2 diabetes mellitus. J Diabetes Res2016, 1–14.
55.
WangH, WangB, YinH, ZhangG, YuL, KongX, YuanH, FangX, LiuQ, LiuC, ShiL (2017) Reduced neurotrophic factor level is the early event before the functional neuronal deficiency in high-fat diet induced obese mice. Metab Brain Dis32, 247–257.
LiuL, CavanaughJE, WangY, SakagamiH, MaoZ, XiaZ (2003) ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci U S A100, 8532–8537.
58.
WangY, SuB, XiaZ (2006) Brain-derived neurotrophic factor activates ERK5 in cortical neurons via a Rap1-MEKK2 signaling cascade. J Biol Chem281, 35965–35974.
59.
LiuW, Ruiz-VelascoA, WangS, KhanS, ZiM, JungmannA, Dolores Camacho-MuñozM, GuoJ, DuG, XieL, OceandyD, NicolaouA, GalliG, MüllerOJ, CartwrightEJ, JiY, WangX (2017) Metabolic stress-induced cardiomyopathy is caused by mitochondrial dysfunction due to attenuated Erk5 signaling. Nat Commun8, 494.
60.
LeeR, KermaniP, TengKK, HempsteadBL (2001) Regulation of cell survival by secreted proneurotrophins. Science294, 1945–1948.
61.
Baeza-RajaB, SachsBD, LiP, ChristianF, VagenaE, DavalosD, Le MoanN, RyuJK, SikorskiSL, ChanJP, ScadengM, TaylorSS, HouslayMD, BaillieGS, SaltielAR, OlefskyJM, AkassoglouK (2016) p75 neurotrophin receptor regulates energy balance in obesity. Cell Rep14, 255–268.
WagenerA, GoesslingHF, SchmittAO, MauelS, GruberAD, ReinhardtR, BrockmannGA (2010) Genetic and diet effects on Ppar-α and Ppar-γ signaling pathways in the Berlin Fat Mouse Inbred line with genetic predisposition for obesity. Lipids Health Dis9, 99.
69.
Del OlmoN, Ruiz-GayoM (2018) Influence of high-fat diets consumed during the juvenile period on hippocampal morphology and function. Front Cell Neurosci12, 439.
70.
WardenA, TruittJ, MerrimanM, PonomarevaO, JamesonK, FergusonLB, MayfieldRD, HarrisRA (2016) Localization of PPAR isotypes in the adult mouse and human brain. Sci Rep6, 27618.
71.
KnightEM, MartinsIVA, GümüsgözS, AllanSM, LawrenceCB (2014) High-fat diet-induced memory impairment in triple-transgenic Alzheimer’s disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging35, 1821–1832.
OhtakeN, SaitoM, EtoM, SekiK (2014) Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. Regul Pept190–191, 1–11.
RantamäkiT, KemppainenS, AutioH, StavénS, KoivistoH, KojimaM, AntilaH, MiettinenPO, KärkkäinenE, KarpovaN, VesaL, LindemannL, HoenerMC, TanilaH, CastrénE (2013) The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer’s disease. PLoS One8, e68722.
Blurton-JonesM, KitazawaM, Martinez-CoriaH, CastelloNA, MullerF-J, LoringJF, YamasakiTR, PoonWW, GreenKN, LaFerlaFM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A106, 13594–13599.
80.
KnowlesJK, SimmonsDA, NguyenT-V V, Vander GriendL, XieY, ZhangH, YangT, PollakJ, ChangT, ArancioO, BuckwalterMS, Wyss-CorayT, MassaSM, LongoFM (2013) A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer’s mouse model. Neurobiol Aging34, 2052–2063.
81.
ChoiSH, BylykbashiE, ChatilaZK, LeeSW, PulliB, ClemensonGD, KimE, RompalaA, OramMK, AsselinC, AronsonJ, ZhangC, MillerSJ, LesinskiA, ChenJW, KimDY, van PraagH, SpiegelmanBM, GageFH, TanziRE (2018) Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. Science361, eaan8821.
82.
RodríguezJJ, JonesVC, TabuchiM, AllanSM, KnightEM, LaFerlaFM, OddoS, VerkhratskyA (2008) Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer’s disease. PLoS One3, e2935.
83.
RodríguezJJ, VerkhratskyA (2011) Neurogenesis in Alzheimer’s disease. J Anat219, 78–89.
84.
HerrupK (2015) The case for rejecting the amyloid cascade hypothesis. Nat Neurosci18, 794–799.
85.
BremA-K, SensiSL (2018) Towards combinatorial approaches for preserving cognitive fitness in aging. Trends Neurosci41, 885–897.
86.
BaazaouiN, IqbalK (2018) A novel therapeutic approach to treat Alzheimer’s disease by neurotrophic support during the period of synaptic compensation. J Alzheimers Dis62, 1211–1218.
87.
de PinsB, Cifuentes-DíazC, Thamila FarahA, López-MolinaL, MontalbanE, Sancho-BalsellsA, LópezA, GinésS, Delgado-GarcíaJM, AlberchJ, GruartA, GiraultJ-A, GiraltA (2019) Conditional BDNF delivery from astrocytes rescues memory deficits, spine density and synaptic properties in the 5xFAD mouse model of Alzheimer disease. J Neurosci39, 2441–2458.
